Cover Image
市場調查報告書

兔熱病:開發中產品分析

Tularaemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293888
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
兔熱病:開發中產品分析 Tularaemia - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 75 Pages
簡介

兔熱病(tularaemia)是由一種被稱為土拉桿菌(Francisella tularensis)的細菌所引起的感染病。主要是因被節肢動物(特別是扁虱和蚊子)虰咬感染。 藉由皮膚、結膜囊、口腔咽喉黏膜與感染的動物及動物性物質直接接獨、或攝取到被污染的食品及水、吸入被污染的灰塵粉霧而感染。主要症狀有皮膚潰瘍、淋巴腺腫大和疼痛、發燒、發冷等。治療方法包含了抗生素和健康生活習慣等。

本報告提供兔熱病治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

兔熱病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Grifols, S.A.
  • Merck & Co., Inc.
  • Tetraphase Pharmaceuticals Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 按給藥法
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8757IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2016, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.Tularaemia.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tularaemia Overview
  • Therapeutics Development
    • Pipeline Products for Tularaemia - Overview
    • Pipeline Products for Tularaemia - Comparative Analysis
  • Tularaemia - Therapeutics under Development by Companies
  • Tularaemia - Therapeutics under Investigation by Universities/Institutes
  • Tularaemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Tularaemia - Products under Development by Companies
  • Tularaemia - Products under Investigation by Universities/Institutes
  • Tularaemia - Companies Involved in Therapeutics Development
    • Aradigm Corp
    • Arno Therapeutics Inc
    • DynPort Vaccine Company LLC
    • Emergent BioSolutions Inc
    • EpiVax Inc
    • Grifols SA
    • Merck & Co Inc
    • Tetraphase Pharmaceuticals Inc
  • Tularaemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRI-011225 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tularaemia [strain A] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tularaemia [strain B] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tularaemia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tularemia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
      • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
      • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tularaemia, H2 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Tularaemia - Pipeline by Aradigm Corp, H2 2016
  • Tularaemia - Pipeline by Arno Therapeutics Inc, H2 2016
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2016
  • Tularaemia - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Tularaemia - Pipeline by EpiVax Inc, H2 2016
  • Tularaemia - Pipeline by Grifols SA, H2 2016
  • Tularaemia - Pipeline by Merck & Co Inc, H2 2016
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Tularaemia - Dormant Projects, H2 2016
  • Tularaemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Tularaemia, H2 2016
  • Number of Products under Development for Tularaemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top